Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
- Conditions
- Cancers With NTRK, ROS1, or ALK Gene Fusions
- Registration Number
- NCT03066661
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
- Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
- Willing and able to provide written, signed informed consent
- Medically suitable for treatment with entrectinib (RXDX-101)
Exclusion Criteria
- Currently enrolled in an ongoing clinical study with any other investigational agent
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
1-844-Startrk (782-7875)
🇺🇸San Diego, California, United States